Aristeia Capital’s LB Pharmaceuticals LBRX Stock Holding History

Aristeia Capital’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,270	Closed	-$241K	–	733
2025 Q3	$241K	Buy	+15,270	New	+$242K	0.01%	367

Other funds holding LBRX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

Aristeia Capital's LBRX Position: Q4 2025 in Review

Aristeia Capital sold out of LB Pharmaceuticals (LBRX) in Q4 2025, closing a stake of 15,270 shares — an estimated $241K sold.

Aristeia Capital first reported a position in LBRX in Q3 2025 and held it in 1 quarter. The position peaked at $241K in Q3 2025. 68 funds tracked by Wall St. Rank hold LBRX as of Q4 2025.

Aristeia Capital reported no remaining LB Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Aristeia Capital sold 15,270 LB Pharmaceuticals shares in Q4 2025, an estimated $241K.
Aristeia Capital first reported a position in LB Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Aristeia Capital's LB Pharmaceuticals position peaked at $241K in Q3 2025.
68 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q4 2025.

Based on Aristeia Capital's 13F filing for Q4 2025, filed 17 Feb 2026.